Editas Medicine Inc (EDIT) CFO Sells 5,000 Shares

Editas Medicine Inc (NASDAQ:EDIT) CFO Andrew A. F. Hack sold 5,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $24.31, for a total transaction of $121,550.00. Following the transaction, the chief financial officer now directly owns 5,000 shares of the company’s stock, valued at $121,550. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Editas Medicine Inc (EDIT) opened at $31.62 on Thursday. The company has a market cap of $1,390.00 and a PE ratio of -9.76. Editas Medicine Inc has a fifty-two week low of $13.12 and a fifty-two week high of $36.00. The company has a quick ratio of 10.12, a current ratio of 10.12 and a debt-to-equity ratio of 0.19.

Editas Medicine (NASDAQ:EDIT) last issued its quarterly earnings data on Tuesday, November 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.04). Editas Medicine had a negative net margin of 1,127.03% and a negative return on equity of 70.19%. The business had revenue of $6.28 million during the quarter, compared to the consensus estimate of $2.66 million. During the same quarter last year, the business earned ($0.59) EPS. The firm’s quarterly revenue was up 553.0% compared to the same quarter last year. equities research analysts forecast that Editas Medicine Inc will post -2.92 EPS for the current fiscal year.

Hedge funds have recently made changes to their positions in the company. IHT Wealth Management LLC acquired a new stake in shares of Editas Medicine during the 2nd quarter worth approximately $107,000. Great West Life Assurance Co. Can grew its position in Editas Medicine by 519.9% in the 3rd quarter. Great West Life Assurance Co. Can now owns 4,959 shares of the company’s stock valued at $114,000 after purchasing an additional 4,159 shares during the period. DekaBank Deutsche Girozentrale bought a new position in Editas Medicine during the 2nd quarter valued at $127,000. Bank of America Corp DE lifted its stake in Editas Medicine by 72.2% during the 1st quarter. Bank of America Corp DE now owns 5,936 shares of the company’s stock valued at $133,000 after acquiring an additional 2,489 shares in the last quarter. Finally, Legal & General Group Plc lifted its stake in Editas Medicine by 308.4% during the 2nd quarter. Legal & General Group Plc now owns 8,654 shares of the company’s stock valued at $145,000 after acquiring an additional 6,535 shares in the last quarter. 65.70% of the stock is owned by institutional investors.

A number of equities analysts have weighed in on EDIT shares. ValuEngine raised shares of Editas Medicine from a “sell” rating to a “hold” rating in a research note on Saturday, September 30th. Morgan Stanley restated an “equal weight” rating and set a $28.00 price objective (up previously from $27.00) on shares of Editas Medicine in a report on Friday, October 6th. Zacks Investment Research cut shares of Editas Medicine from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Cowen reissued a “buy” rating on shares of Editas Medicine in a research report on Tuesday, November 7th. Finally, Cann reissued a “hold” rating on shares of Editas Medicine in a research report on Tuesday, November 7th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Hold” and an average price target of $26.73.

ILLEGAL ACTIVITY NOTICE: “Editas Medicine Inc (EDIT) CFO Sells 5,000 Shares” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/11/editas-medicine-inc-edit-cfo-sells-121550-00-in-stock.html.

About Editas Medicine

Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.

Insider Buying and Selling by Quarter for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply